Skip to main content
. Author manuscript; available in PMC: 2012 Feb 1.
Published in final edited form as: J Clin Psychopharmacol. 2011 Feb;31(1):22–30. doi: 10.1097/JCP.0b013e31820465fa

Table 1.

Pretreatment Demographic and Clinical Measures1

Placebo Sertraline Significance Level4

EOAs2 (n=25) LOAs3 (n=46) EOAs2 (n=21) LOAs3 (n=42) Treatment Age of Onset Interaction
Demographic Features
Sex (% male) 84.0 78.3 95.2 73.8 0.92 0.07 0.19
Race (% white) 100 89.1 90.5 90.5 0.60 0.24 0.13
Age (years) 42.2 (10.8) 50.1 (7.5) 44.1 (10.9) 49.5 (9.3) 0.81 <0.001 0.45
Education (years) 14.0 (2.1) 15.2 (2.4) 14.4 (2.5) 14.1 (2.0) 0.13 0.22 0.07
Clinical Features
Number of DSM-IV Criteria for AD5 6.2 (1.1) 5.7 (1.1) 6.3 (0.7) 6.0 (1.0) 0.32 0.02 0.64
Drinking Days (%) 62.7 (28.6) 71.4 (25.3) 70.2 (22.6) 66.0 (27.8) 0.84 0.57 0.18
Heavy Drinking Days (%) 56.8 (30.0) 61.2 (28.0) 57.8 (31.6) 50.6 (30.1) 0.19 0.84 0.29
Mean Drinks Per Day 6.7 (4.1) 6.1 (3.8) 7.7 (5.9) 6.0 (4.3) 0.74 0.17 0.47
Short Index of Problems Score 23.4 (7.5) 20.8 (8.6) 24.1 (8.0) 19.1 (9.2) 0.53 0.02 0.42
Lifetime Major Depression (%) 20.0 23.9 28.6 14.3 0.62 0.53 0.21
Beck Depression Inventory Score 6.7 (5.7) 6.4 (5.6) 7.2 (5.8) 5.5 (6.5) 0.68 0.35 0.52
1

Mean (SD) or percentage;

2

EOAs: Early-Onset Alcoholics;

3

LOAs: Late-Onset Alcoholics;

4

F-test for continuous measures and χ2 test for categorical measures;

5

Current alcohol dependence